Healthcare investing puts a hard question to Christians: how do you own a sector that heals the sick — plainly good work — when corners of it profit from abortion, embryo destruction, and assisted death? The workable answer is to screen at the issue level, lean on funds that already do the digging, and accept that some gray is unavoidable.
No other corner of the market mixes obvious good and serious moral hazard as tightly as healthcare does. The same companies that make cancer drugs and surgical tools may also manufacture abortifacients or have tested products on cell lines derived from an aborted child decades ago. That entanglement is why healthcare sits among the toughest calls in Christian investment screening, and why a blanket “avoid pharma” rule serves nobody well. Done right, Christian healthcare investing is less about boycotts and more about discernment. Let’s work through what is actually at stake and how to make a clear-eyed decision.
Why Healthcare Is the Hardest Screen to Get Right
Scripture treats healing as a good. Jesus spent much of his ministry restoring sight, mobility, and life, and the Good Samaritan is praised precisely for paying a stranger’s medical bills (Luke 10:34-35). A Christian has every reason to want capital flowing toward companies that cure disease and ease suffering. That is faithful stewardship, not a compromise.
The trouble is that the sector bundles that good with practices a Christian conscience cannot bless. A single large pharmaceutical firm might run an oncology division you would gladly fund, a contraceptive line that includes abortifacient products, and a research pipeline that once relied on fetal cell lines. You cannot buy the cancer drugs without buying the whole company. That is the bind, and honest screening starts by admitting it rather than pretending healthcare is either all clean or all corrupt.
The Bioethical Flashpoints
Abortion and Abortifacients
This is the center of gravity. “You formed my inward parts; you knitted me together in my mother’s womb” (Psalm 139:13). “Before I formed you in the womb I knew you” (Jeremiah 1:5). For Christians who hold that the unborn child bears God’s image (Genesis 1:27), companies that manufacture abortion drugs such as mifepristone, produce abortifacient contraceptives, or fund abortion-advocacy groups cross a bright line. Screening here means identifying not just clinic operators but the drug makers and corporate donors behind the practice.
Embryonic Stem Cells and Fetal Cell Lines
Some research and manufacturing has historically used cell lines originally derived from aborted fetuses — HEK293 being the best known. A number of widely used drugs and vaccines were tested against these lines. Christians divide on how much moral weight a decades-old derivation carries today, but for many it is a real factor, and Catholic screens in particular flag embryonic stem cell research and destructive embryo experimentation as disqualifying.
Assisted Suicide and Euthanasia
“You shall not murder” (Exodus 20:13) and “I have set before you life and death… therefore choose life” (Deuteronomy 30:19) shape how many Christians view the growing market around physician-assisted death. Few public companies are pure-play here, but the issue surfaces in hospital systems, pharmacy chains, and insurers operating where assisted death is legal. It belongs on the radar even if it rarely drives a single buy-or-sell decision.
Gene Editing and the Germline
CRISPR-based therapies have already cured sickle cell disease, which is a genuine good. The concern is not gene therapy itself but the line between treating a sick patient and editing the human germline — heritable changes to embryos that raise designer-baby and eugenics questions. Most Christian ethicists distinguish sharply between healing an existing person and re-engineering future ones. Watch which side of that line a company’s pipeline sits on.
How Christian Traditions Diverge
There is no single “Christian” healthcare screen, because traditions weigh these issues differently. Knowing where you stand keeps you from outsourcing your conscience to a fund that screens on convictions you do not share.
| Tradition | Typical emphasis | Where it lands |
|---|---|---|
| Catholic | Abortion, contraception, embryonic stem cells, euthanasia | Broadest screens; guided by Church teaching and USCCB-informed criteria |
| Evangelical | Abortion and abortifacients above all | Sharp focus on life issues; more permissive on contraception |
| Mainline Protestant | Access, equity, patient welfare | Often lighter exclusions; engagement over avoidance |
None of these is “the” right answer for every believer. A Catholic investor and an evangelical investor can both screen faithfully and still hold different portfolios, because they are applying different but sincerely held convictions. The point is to choose deliberately. If the avoid-versus-engage distinction is new to you, our overviews of negative screening and positive screening lay out both approaches.
What the Screened Funds Actually Do
Most investors should not try to vet forty drug makers alone. Several fund families already maintain healthcare screens you can read and trust to a point.
- Ave Maria applies Catholic moral criteria, excluding companies involved in abortion, abortifacient contraception, and embryonic stem cell research. Our Ave Maria review walks through its specific screens.
- Timothy Plan screens abortion and abortifacient involvement from an evangelical standpoint; see our Timothy Plan review.
- Eventide pairs avoidance with a positive thesis and runs a dedicated healthcare and life-sciences fund, which makes its biotech holdings worth a close read.
Read each fund’s published methodology rather than the marketing. Two funds that both call themselves pro-life may draw the abortifacient line in different places. And remember that even a strict screen cannot remove every trace of entanglement in a sector this interconnected.
A Practical Framework for Your Own Holdings
Here is a sequence that turns conviction into a portfolio you can defend.
- Name your non-negotiables. Decide which issues are dealbreakers and which are factors you will weigh. Abortion involvement is a hard line for most; fetal-cell-line history may be a softer weighting.
- Read the fund screens. Pull the written policy for any healthcare-heavy fund you own and confirm it matches your convictions, not just its tagline.
- Audit what you already hold. Look through your index funds — a total-market fund almost certainly owns the major pharma names. This is where most Christians discover hidden exposure.
- Accept the gray. You will not reach moral purity in a sector this tangled. Aim for a clear conscience and consistent principles, not the impossible standard of zero contact with anything objectionable.
- Revisit yearly. Companies merge, pipelines change, and a clean holding can acquire a troubling division. Re-screen on a schedule.
If you want to broaden this discipline beyond healthcare, the same logic applies to other hard sectors like defense stocks and the classic sin stocks. For the foundation under all of it, start with what biblically responsible investing is.
The Hidden Exposure Most Christians Miss
Here is the uncomfortable reality for anyone with a workplace retirement plan. If your 401(k) sits in a target-date fund or a total-market index fund, you almost certainly own every major healthcare and pharmaceutical company in the index — including the ones whose products you would never buy directly. Most people never notice, because the holdings are buried three layers down in a fund-of-funds. The first faithful step is often just opening the holdings report and reading it. You cannot screen what you have never looked at.
The same goes for broad sector ETFs. A health-care sector fund holds drug makers, device companies, insurers, and hospital operators side by side, with no distinction between the firm curing leukemia and the firm marketing an abortifacient. Once you see the exposure, you have three honest options: switch to a screened fund, rebuild the sleeve from individual names you have vetted, or stay invested and use your shareholder voice. Each is defensible; drifting along in ignorance is the one choice that is not.
When to Engage Instead of Exit
Avoidance is not the only biblical posture. Some Christians keep a holding precisely so they can vote proxies, file resolutions, and press management toward better practices — salt and light inside the company rather than a clean exit. This engagement route fits investors with the patience and scale to make it count, and it can move companies that a simple sell-off never would.
The tradeoff is real: engagement means continuing to profit from a business while you work to change it, which not every conscience can carry. Avoidance keeps your hands clean but cedes your seat at the table. Neither is cowardice or compromise on its own; the question is which one you can pursue with integrity. Many investors blend the two — exiting the worst offenders outright while engaging the companies that are merely imperfect.
Frequently Asked Questions
Should Christians avoid all pharmaceutical stocks?
No. Drug companies that develop life-saving medicines do work Scripture would call good. The goal is to avoid specific involvement in abortion, embryo destruction, and assisted death, not to boycott medicine itself. A screened fund or a careful holdings review lets you support healing while declining to profit from the practices you oppose.
Do my index funds own abortion-related companies?
Almost certainly. A total-market or S&P 500 index fund holds the large pharmaceutical and healthcare firms, some of which have abortifacient products or related involvement. If that troubles you, a screened Christian fund or a self-built portfolio that excludes flagged names is the practical fix. Check your holdings list to see exactly what you own.
How do I research a single company’s involvement?
Start with the company’s product list and annual report, then cross-check against pro-life research databases and the screening notes published by Christian fund families. Focus on what the company makes and funds, not rumors. When the data is ambiguous, weigh it against your stated non-negotiables and decide rather than stall.
